InvestorsHub Logo
Followers 17
Posts 3780
Boards Moderated 0
Alias Born 02/21/2009

Re: joe_techi post# 14030

Friday, 09/16/2016 9:27:27 AM

Friday, September 16, 2016 9:27:27 AM

Post# of 64388
NPHC's FDA Orphan designation is going to really reduce the costs associated with a Phase 2 and 3 trial. Add Dr VanderPutten and his contacts with government and universities and the recent Manufacturing Alliance With Omnia Biologics to Produce RPI-78M for Clinical Trials will reduce costs even further.

NPHC is moving forward with their drugs again. IMO, shares are on sale at these prices.